Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3

ClinicalTrials.gov ID: NCT05461105

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05461105. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

ALTITUDE NASH: A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis Stage 3 Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, open-label, parallel-dosing, multi-center study to evaluate the safety and efficacy of rencofilstat as evidenced by assessing changes in the HepQuant Shunt Disease Severity Index Score (DSI), safety labs, and clinical events in adult NASH subjects with compensated Fibrosis stage F 2/3. Antifibrotic biomarker activity will be evaluated on an exploratory basis.

Study identification

NCT ID
NCT05461105
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Enrollment
60 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 15, 2022 (Actual)
Primary completion
Apr 15, 2023 (Actual)
Completion
Jul 7, 2023 (Actual)
Last update posted
Jun 13, 2024

2022 – 2023

United States locations

U.S. sites
20
U.S. states
7
U.S. cities
19
Facility City State ZIP Site status
Arizona Liver Health-Chandler Chandler Arizona 85224 —
Arizona Liver Health-Glendale Peoria Arizona 85381 —
Adobe Clinical Research, LLC Tucson Arizona 85712 —
Arizona Liver Health-Tucson Tucson Arizona 85712 —
Velocity Clinical Research-Chula Vista Chula Vista California 91911 —
Velocity Clinical Research-San Diego La Mesa California 91942 —
Synergy Healthcare, LLC Bradenton Florida 34208 —
Covenant Metabolic Specialists-Fort Myers Fort Myers Florida 33912 —
Evolution Clinical Trials, Inc. Hialeah Gardens Florida 33016 —
Progressive Medical Research Port Orange Florida 32127 —
Covenant Metabolic Specialists-Sarasota Sarasota Florida 34240 —
Clinical Research Institute of Michigan Chesterfield Michigan 48047 —
Coastal Reseach Institute Fayetteville North Carolina 28304 —
Optimed Research Columbus Ohio 43235 —
Clinical Research Institute of Ohio Westlake Ohio 44145 —
Pinnacle Clinical Research-Austin Austin Texas 78757 —
Apex Mobile Clinical Research Bellaire Texas 77401 —
South Texas Research Institute Edinburg Texas 78539 —
Pinnacle Clinical Research-Georgetown Georgetown Texas 78626 —
Pinnacle Clinical Research-San Antonio San Antonio Texas 78229 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05461105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 13, 2024 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.